ClinicalTrials.gg
RecruitingNCT07612176Updated Sep 25, 2026

A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

A Phase 1 interventional study of NEOK001 and NEOK001 RDE in Locally Advanced (Unresectable) or Metastatic Solid Tumors, sponsored by NEOK Bio, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by NEOK Bio, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
155
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,055 studies in Neoplasm Metastasis with a site in United States — 347 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
376th of 1,864
155 · median 43
Started
2026
with 83 others
Phase 1
710 of 2,055
129 open now
Primary completion
2029-01
later than 453 of 541 live
Registered
2,024th of 2,055
by date

Among the 2,055 studies in Neoplasm Metastasis with a site in United States, this one is the 376th largest by planned enrollment of the 1,864 interventional ones that give a count, is one of 84 that started in 2026, is one of 710 in phase 1, reaches primary completion later than 453 of the 541 other live ones, and was the 2,024th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

347 of the 2,055 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,055 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Read the detailed description

This is a FIH, Phase 1, open-label, multicenter, multiple-dose, dose escalation and expansion study. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B). NEOK001 is a bispecific B7-H3 x ROR1 exatecan antibody-drug conjugate (ADC) that will be administered intravenously once every cycle.

03

Conditions studied

  • Locally Advanced (Unresectable) or Metastatic Solid Tumors

Keywords

  • Antibody-Drug Conjugate
  • ADC
  • Bispecific
  • B7-H3
  • ROR1
  • Locally Advanced
  • Unresectable
  • Metastatic
  • Solid Tumor
  • oncology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have locally advanced or disease in a select tumor type, for which no standard therapy is available.
  • Participants must have at least 1 measurable target lesion based on v1.1.
  • Participants must have (ECOG) performance status of 0 or 1.
  • Participants must have adequate hematologic, hepatic, and renal function.
  • Participants should have available archived tumor tissue from their most recent .

Key Exclusion Criteria:

  • Participant's most recent systemic anti-cancer treatment was an ADC with a topoisomerase 1-inhibitor payload component.
  • Participants with known symptomatic central nervous system (CNS) metastases or any evidence of or evidence of unstable , even if asymptomatic.
  • Participants with a known history of interstitial lung disease (ILD) requiring treatment, or for whom suspected ILD cannot be ruled out by imaging at screening.
  • Participants with clinically severe pulmonary compromise due to intercurrent pulmonary illness and/or pulmonary disorder requiring supplemental oxygen or any prior pneumonectomy.
  • Participants with a corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Drug: NEOK001

  • Experimental
    Expansion

    Drug: NEOK001 RDE

Interventions

  • DrugNEOK001

    Escalating doses of NEOK001

  • DrugNEOK001 RDE

    Recommended Dose of NEOK001 for Expansion

06

What researchers measure

Primary outcomes

  1. Part A: Incidence and Severity of Dose-Limiting Toxicities (DLTs)

    Incidence and severity of DLTs during the first cycle of treatment in Part A

    Time frame: 21 Days

  2. Part A: Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in participants in Part A

    Time frame: Through study completion, estimated as 32 months

  3. Part B: Investigator Assessment of Objective Response Rate (ORR)

    Percentage of participants who achieve a confirmed objective response (ORR)

    Time frame: Through study completion, estimated as 32 months

  4. Part B: Duration of Response (DOR)

    The time from the first documentation of tumor response (complete or partial) until disease progression or death.

    Time frame: Through study completion, estimated as 32 months

Secondary outcomes

  1. Part B: Incidence of AEs

    Incidence of TEAEs and SAEs in participants in Part B

    Time frame: Through study completion, estimated as 32 months

  2. Maximum Concentration (Cmax)

    Assessment of plasma pharmacokinetics (PK) of NEOK001 maximum observed concentration (Cmax) of NEOK001.

    Time frame: 21 days

  3. Terminal Elimination Half Life (T1/2)

    Assessment of plasma PK of NEOK001 terminal elimination half-life (T1/2).

    Time frame: 21days

07

Study locations

9 of 9 sites recruiting
08

References and documents

Publications

  • Kwon JA, Lee S, Kim J, Yoo BM, Park HJ, Ryu I, Kim J, Eom J, Son YG, Yeom D, Sung B, Yoo M, Seo A, Yoo J, Park JY, Jung J, Ahn J, You WK, Lee SH, Ko MJ. Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1. MAbs. 2026 Dec;18(1):2731283. doi: 10.1080/19420862.2026.2731283. Epub 2026 Sep 12. PubMed 42731893 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2029, 33 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 33 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 28, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42731893 ↗
Sep 25, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • SCRI at Mary Crowley · Dallas, United StatesContact T•••@scri.com · •••3000→M•••@scri.com · •••3000
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42731893 ↗
    Site contacts Changed at 1 site. See the sites
    Show the site
    • SCRI at Mary Crowley · Dallas, United StatesContact T•••@scri.com · •••3000→M•••@scri.com · •••3000

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07612176
Lead sponsor
NEOK Bio, Inc.
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Apr 21, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 25, 2026

Study contacts

Willie J Hudson, MS
Contact
whudson@neokbio.com
615-507-4263

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion